BridgeMD
New treatment option for Ischemic Stroke
Official title Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
ClinicalTrials.gov ID: NCT06653348
What this study is testing
What is Ticagrelor 60 + Aspirin?
Ticagrelor 60 + Aspirin is an investigational medicine, given as an once-daily infusion into a vein, being studied as a potential treatment for ischemic stroke.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 6 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older. Healthy volunteers may be eligible.
You may be able to join if
- signing inform consent,
- recent ischemic stroke within 24 h,
- diagnosed by brain CT or MRI mild stroke with NIHSS =\<8 and no evidence of large infarct in brain imaging
- high risk TIA with ABCD \>4,
- no cardioembolic source such as low E/F, MS, AF ,...
You likely can't join if
- history of hypersensitivity to consumptive drug
- any indication for anticoagulant therapy
- acute phase treatment with intravenous thrombolysis or thrombectomy
- any contraindication for consumptive drug
- history of intracranial hemorrhage
- history of GI bleeding during past 6 m
See the full eligibility criteria
- signing inform consent,
- recent ischemic stroke within 24 h,
- diagnosed by brain CT or MRI mild stroke with NIHSS =\<8 and no evidence of large infarct in brain imaging
- high risk TIA with ABCD \>4,
- no cardioembolic source such as low E/F, MS, AF ,...
- no specific etiology such as dissection, vasculitis, ...
- no carotid stenosis \> 50 % in side of involvement
- history of hypersensitivity to consumptive drug
- any indication for anticoagulant therapy
- acute phase treatment with intravenous thrombolysis or thrombectomy
- any contraindication for consumptive drug
- history of intracranial hemorrhage
- history of GI bleeding during past 6 m
- candidate for endarterectomy
- history of coagulopathy
- active hemorrhagic diathesis during randomization
The study team makes the final eligibility decision.
Where it's taking place
- Sari, Mazandaran, Iran
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Sari, Mazandaran, Iran. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.